Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Videocapillaroscopic Findings in Hand Osteoarthritis

11 de noviembre de 2026 actualizado por: Nurten NAS KIRDAR, Bandırma Onyedi Eylül University

Association of Nailfold Videocapillaroscopy Findings With Clinical, Functional, and Radiological Characteristics in Primary Hand Osteoarthritis: A Comparative Cross-Sectional Study With Healthy Controls

The purpose of this study is to compare microvascular changes-assessed via nailfold videocapillaroscopy-in patients with primary hand osteoarthritis against a healthy control group, and to investigate the relationship between capillaroscopic findings and disease severity, functional status, and clinical characteristics.

Descripción general del estudio

Estado

Aún no reclutando

Descripción detallada

In this context, the associations between capillaroscopic parameters and the Kellgren-Lawrence radiological grading, handgrip strength, the Functional Index for Hand Osteoarthritis (FIHOA), and the Australian/Canadian Osteoarthritis Hand Index (AUSCAN) scores will be evaluated. Furthermore, the study aims to determine the potential clinical value of nailfold videocapillaroscopy in identifying microvascular alterations associated with primary hand osteoarthritis.

Tipo de estudio

De observación

Inscripción (Estimado)

130

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Nurten NAS KIRDAR, Assistant Professor
  • Número de teléfono: +905415511691
  • Correo electrónico: nkirdar@bandirma.edu.tr

Copia de seguridad de contactos de estudio

  • Nombre: Ayşegül ÖZDOĞAN BİRCAN, Specialist Physician

Ubicaciones de estudio

    • Balıkesir
      • Bandırma, Balıkesir, Turquía (Türkiye), 10200
        • Bandırma Onyedi Eylul University Faculty of Medicine
        • Contacto:
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra de probabilidad

Población de estudio

The study population will consist of patients diagnosed with primary hand osteoarthritis and age- and sex-matched healthy controls. Participants will undergo clinical assessment, hand function evaluation, radiographic assessment, and nailfold videocapillaroscopy.

Descripción

Inclusion Criteria:

  • Patient group (Primary hand osteoarthritis)

    • Being 18 years of age or older.
    • Having a diagnosis of primary hand osteoarthritis in accordance with the 2018 EULAR recommendations.
    • Being willing to participate in the study and having signed the written Informed Consent Form.
    • Being able to undergo clinical assessment, nailfold videocapillaroscopy, and the necessary functional evaluations.
    • Having hand radiographs of sufficient quality to be evaluated according to the Kellgren-Lawrence classification system.

Healthy control group

  • Being 18 years of age or older.
  • Having no diagnosis of inflammatory rheumatologic disease or primary hand osteoarthritis.
  • Being willing to participate in the study and having signed the written Informed Consent Form.
  • Being similar to the patient group in terms of age and gender.
  • Being able to undergo nailfold videocapillaroscopy assessment.

Exclusion Criteria:

  • Patient group

    • Being under 18 years of age.
    • Diagnosis of secondary osteoarthritis of the hand (due to trauma, infection, metabolic, or other causes).
    • Presence of rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, systemic sclerosis, Sjögren's syndrome, inflammatory myopathies, vasculitis, or other connective tissue diseases.
    • History of Raynaud's phenomenon.
    • History of malignancy.
    • Chronic renal failure (stage 4-5) or advanced liver failure.
    • Active infection or a serious infection within the last four weeks.
    • Pregnancy or breastfeeding.
    • History of a neurological condition that could affect hand grip strength (e.g., hemiplegia, tetraplegia, peripheral nerve injury, or other neurological/neuromuscular disorders resulting in loss of muscle strength).
    • History of trauma, surgical intervention, or any procedure affecting the nail bed of the fingers within the last month.
    • Presence of an open wound, active infection, severe dermatological condition, or deformity that would hinder the assessment of the nail fold.
    • Refusal to participate in the study or failure to sign the informed consent form.

Healthy control group

In addition to the exclusion criteria listed above:

  • Diagnosis of primary osteoarthritis of the hand or any inflammatory rheumatic disease.
  • Presence of hand pain or any chronic musculoskeletal disorder that affects hand function.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: CASE_CONTROL
  • Perspectivas temporales: CROSS_SECTIONAL

Cohortes e Intervenciones

Grupo / Cohorte
hand osteoarthritis group

hand osteoarthritis group;

  • Being 18 years of age or older.
  • Having a diagnosis of primary hand osteoarthritis in accordance with the 2018 EULAR recommendations.
  • Being willing to participate in the study and having signed the written Informed Consent Form.
  • Being capable of undergoing clinical assessment, nailfold videocapillaroscopy, and the necessary functional evaluations.
  • Having hand radiographs of sufficient quality to be evaluated according to the Kellgren-Lawrence classification system.
control group

control group;

  • Being 18 years of age or older.
  • Absence of a diagnosis of inflammatory rheumatic disease or primary osteoarthritis of the hand.
  • Willingness to participate in the study and having signed the written Informed Consent Form.
  • Having characteristics similar to the patient group in terms of age and gender.
  • Being able to undergo the nailfold videocapillaroscopy assessment.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Nailfold videocapillaroscopic microvascular parameters
Periodo de tiempo: 6 months

The primary outcome is the comparison of nailfold videocapillaroscopic microvascular parameters between patients with primary hand osteoarthritis and healthy controls.

Nailfold videocapillaroscopy will be performed using the Dino-Lite Capillary Scope Pro200 digital microscope and DinoCapture v2.0 software. Prior to the examination, participants will be required to rest for at least 15 minutes in a room maintained at a constant temperature of 20-22°C; they will also be instructed to refrain from smoking or consuming caffeine for at least 30 minutes before the procedure. Participants will be questioned regarding any recent manicures, nail-biting, local trauma, or other procedures that might affect the nail bed. During the examination, the hands will be kept at the level of the heart, and immersion oil will be applied to the nailfold. The second through fifth digits of both hands will be evaluated at ×200 magnification, and images of two 1 mm areas from each digit will be recorded.

6 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Kellgren-Lawrence classification
Periodo de tiempo: 6 months

Participants' hand radiographs will be evaluated for signs of osteoarthritis. The presence of osteophytes, joint space narrowing, subchondral sclerosis, cystic changes, and deformities in the distal interphalangeal, proximal interphalangeal, and first carpometacarpal joints will be recorded. The radiological severity of the disease will be graded from 0 to 4 for each joint using the Kellgren-Lawrence classification: grade 0, no radiological evidence of osteoarthritis; grade 1, questionable joint space narrowing and possible osteophytes; grade 2, definite osteophytes and possible joint space narrowing; grade 3, multiple osteophytes, definite joint space narrowing, sclerosis, and possible bone contour deformity; and grade 4, severe joint space loss, large osteophytes, marked sclerosis, and bone deformity. Radiographic hand osteoarthritis will be defined, in general, as a Kellgren-Lawrence grade of ≥2.

6 months
Australian/Canadian Osteoarthritis Hand Index (AUSCAN)
Periodo de tiempo: 6 months

Disease-related pain, stiffness, and functional impairment will be assessed using the Australian/Canadian Osteoarthritis Hand Index (AUSCAN). AUSCAN is a 15-item, patient-reported outcome measure developed for hand osteoarthritis, comprising subscales for pain (5 items), morning stiffness (1 item), and physical function (9 items). The function subscale evaluates difficulty with activities of daily living, such as turning on a faucet, operating a doorknob, buttoning clothes, opening a jar, carrying heavy objects, and grasping small items. The scale can be administered using Likert, visual analog, or numerical rating formats; the specific version and scoring method to be used in this study will be standardized in advance. Higher scores indicate more severe symptoms and greater loss of function.

6 months
Functional Index for Hand Osteoarthritis (FIHOA/Dreiser Index)
Periodo de tiempo: 6 months

Functional impairment due to hand osteoarthritis will also be assessed using the Functional Index for Hand Osteoarthritis (FIHOA/Dreiser Index). The FIHOA is a 10-item scale that evaluates daily hand functions, such as using a key, cutting with a knife, opening a bottle or jar, buttoning, writing, lifting objects, and shaking hands. Each item is scored on a scale of 0-3, with a total score ranging from 0-30; a higher score indicates greater functional impairment. The validity and reliability of the Turkish version of the FIHOA have been established, and it has been reported to demonstrate high internal consistency and test-retest reliability.

6 months
Handgrip strength
Periodo de tiempo: 6 months

Grip strength will be measured separately for each hand using a standard hand dynamometer (Baseline brand, 200 lb LITE hydraulic hand dynamometer). During the measurement, the participant will be in a seated position, with the shoulder in adduction and neutral rotation, the elbow flexed at approximately 90°, the forearm in a neutral position, and the wrist in slight extension. Three measurements will be taken for each hand, with short rest intervals between them; the analysis will utilize either the mean of these measurements or the highest value, in accordance with a pre-established protocol. The brand and model of the dynamometer used will be specified in the research form. Grip strength measurements obtained via a hand dynamometer have been shown to be reliable in patients with hand osteoarthritis.

6 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Nurten NAS KIRDAR, Bandırma Onyedi Eylül University

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

20 de noviembre de 2026

Finalización primaria (Estimado)

20 de abril de 2027

Finalización del estudio (Estimado)

30 de abril de 2027

Fechas de registro del estudio

Enviado por primera vez

11 de noviembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

11 de noviembre de 2026

Publicado por primera vez (Actual)

17 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

17 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

11 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • E-67961857-050.04-2600065387

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Descripción del plan IPD

Individual participant data (IPD) will not be shared with other researchers due to patient confidentiality and data privacy considerations. Only anonymized aggregate data may be reported in the publication.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir